Search in Brand
Filter Your Search
Shop by Category
Boehringer Ingelheim
Pyramid 5 + Presponse SQ 20mL - 10 Dose
Modified-live virus for vaccination of healthy dairy or beef cattle as an aid in the prevention of disease caused by IBR, BVD Types 1&2, PI3 and BRSV, and as an aid in reduction of severity of pneumonic pasteurellosis caused by Mannheimia haemolytica. A DOI of 217 days has been demonstrated against respiratory disease caused by BVD Type 1b. Vaccination provides a protective effect against development of post-challenge viremia and leukopenia.
Pyramid 5 20mL - 10 Dose
Modified-live virus for vaccination of healthy cattle as an aid in the prevention of disease caused by IBR, BVD Types 1 & 2, PI3 and BRSV. A DOI of 217 days has been demonstrated against respiratory disease caused by BVD Type 1b. Vaccination provides a protective effect against development of post-challenge viremia and leukopenia. Also aids in the prevention of persistent BVD Types 1 & 2 infection of the fetal calf when used subcut in the cow or heifer 30-60 days pre-breeding. May be used in pregnant cows or calves nursing pregnant cows provided cows were vaccinated pre-breeding, according to label instructions, with any Express FP vaccine, Pyramid 5, Pyramid 10 or Pyramid 5 + Presponse SQ.
Triangle 10 HB 250mL - 50 Dose
For vaccination of healthy cattle as an aid in the prevention of disease caused by BVD Types 1&2, PI3, BRSV and the 5 most common strains of Lepto, including L. hardjo-bovis, prevention of urinary shedding of L. hardjo-bovis in heifers 10 months of age or older, and as an aid in the reduction of disease due to IBR. Vaccinated animals subsequently exposed to L. hardjo-bovis have been shown to clear renal infections within 8 weeks of exposure.
Pyramid 5 + Presponse SQ 100mL - 50 Dose
Modified-live virus for vaccination of healthy dairy or beef cattle as an aid in the prevention of disease caused by IBR, BVD Types 1&2, PI3 and BRSV, and as an aid in reduction of severity of pneumonic pasteurellosis caused by Mannheimia haemolytica. A DOI of 217 days has been demonstrated against respiratory disease caused by BVD Type 1b. Vaccination provides a protective effect against development of post-challenge viremia and leukopenia.